In patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who had progressed on or after platinum-based chemotherapy, an ORR of 40% (95% CI 29–51) was seen. Here, EGFR is linked to non-small cell lung carcinoma.